ClinicalTrials.gg

Program

Esflurbiprofen Topical System

Its studies are led by Teikoku Seiyaku.

Furthest: phase 1, since Jan 19, 20253 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Teikoku Seiyaku30 open or runningphase 1since Jan 19, 2025Jan 19, 2025none ahead

Also a collaborator on its studies: SocraMetrics, HWI pharma services and CRM Biometrics.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 19, 2025First study: phase 1 study in HealthyFirst studyNCT06823284 · 26 enrolled · Germany
  2. Mar 6, 2025Phase 1 study in HealthyNCT06870422 · 28 enrolled · Germany
  3. Dec 15, 2025Phase 1 study in Healthy ParticipantsNCT07307794 · 90 enrolled · Germany

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07307794Healthy Participants · Germany1CompletedMar 3, 202690
NCT06870422Healthy · Germany1CompletedApr 3, 202528
NCT06823284Healthy · Germany1CompletedFeb 12, 202526

How it is read

Names in the registry

  • “Esflurbiprofen Topical System”, 3 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.